Getting to heart of ‘a-fib,’ East Bay company plans for late-stage drug trial, more cash

The company hopes to start its first Phase III trial this summer to show that its inhalable version of a generic drug can correct atrial fibrillation in a matter of minutes, instead of hours or days.